Download PDF
J Knee Surg 2016; 29(07): 564-570
DOI: 10.1055/s-0035-1568992
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Association between Hyaluronic Acid Injections and Time-to-Total Knee Replacement Surgery

Roy Altman
1   Department of Medicine, University of California at Los Angeles, Los Angeles, California
,
Michael Fredericson
2   PM&R Sports Medicine, Stanford University, Pavilion A Redwood City, California
,
Samir K. Bhattacharyya
3   DePuy Synthes Mitek Sports Medicine (a Johnson & Johnson Co.), Raynham, Massachusetts
,
Brad Bisson
3   DePuy Synthes Mitek Sports Medicine (a Johnson & Johnson Co.), Raynham, Massachusetts
,
Thomas Abbott
4   HCL Technologies, Philadelphia, Pennsylvania
,
Sashidhar Yadalam
5   Epidemiology and Health Informatics, Johnson and Johnson Co., New Brunswick, New Jersey
,
Myoung Kim
5   Epidemiology and Health Informatics, Johnson and Johnson Co., New Brunswick, New Jersey
› Author Affiliations
Further Information

Publication History

30 September 2015

10 October 2015

Publication Date:
07 December 2015 (online)

    Permissions and Reprints

Abstract

This study assessed the association between hyaluronic acid (HA) injections and time-to-total knee replacement (TKR) surgery for patients with knee osteoarthritis (OA). Patients 18 to 64 years of age who had TKR surgery between January 1, 2006 and December 31, 2011 were identified from the MarketScan Commercial claims database. All patients had 6 years or more of continuous enrollment prior to TKR surgery. There were two cohorts (1) patients with HA injections prior to TKR surgery and (2) patients who did not have HA injections prior to TKR surgery. Time-to-TKR was defined as the total days from the date of diagnosis of knee OA on the patient's first visit to an orthopedic surgeon to the date of TKR surgery. Results included 22,555 patients who had TKR surgery: 14,132 in the non-HA and 8,423 in the HA cohort. In this retrospective analysis of patients undergoing TKR, the median Time-to-TKR surgery was 326 days for the non-HA and 908 days for the HA cohort, a difference of 582 days. Those receiving HA injections had a median 1.6-year longer Time-to-TKR surgery versus those who did not receive HA injections. These results have both clinical and economic implications.

Keywords

hyaluronic acid - knee osteoarthritis - total knee replacement surgery - viscosupplementation
 

  • References

  • 1 Lawrence RC, Felson DT, Helmick CG , et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58 (1) 26-35
    CrossrefPubMedGoogle Scholar
  • 2 Centers for Disease Control and Prevention. A National Public Health Agenda for Osteoarthritis; 2010. Atlanta, GA. www.cdc.gov/arthritis/docs/OAagenda.pdf . Accessed May 5, 2015
    PubMedGoogle Scholar
  • 3 Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991–94. J Rheumatol 2006; 33 (11) 2271-2279
    PubMedGoogle Scholar
  • 4 Fibel KH, Hillstrom HJ, Halpern BC. State-of-the-Art management of knee osteoarthritis. World J Clin Cases 2015; 3 (2) 89-101
    PubMedGoogle Scholar
  • 5 Kopec JA, Rahman MM, Berthelot JM , et al. Descriptive epidemiology of osteoarthritis in British Columbia, Canada. J Rheumatol 2007; 34 (2) 386-393
    PubMedGoogle Scholar
  • 6 Oleske DM, Bonafede MM, Jick S, Ji M, Hall JA. Electronic health databases for epidemiological research on joint replacements: considerations when making cross-national comparisons. Ann Epidemiol 2014; 24 (9) 660-665
    CrossrefPubMedGoogle Scholar
  • 7 Silverwood V, Blagojevic-Bucknall M, Jinks C, Jordan JL, Protheroe J, Jordan KP. Current evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage 2015; 23 (4) 507-515
    CrossrefPubMedGoogle Scholar
  • 8 Arnold W, Fullerton DS, Holder S, May CS. Viscosupplementation: managed care issues for osteoarthritis of the knee. J Manag Care Pharm 2007; 13 (4, Suppl) S3-S19 , quiz S20–S22
    PubMedGoogle Scholar
  • 9 Murphy L, Helmick CG. The impact of osteoarthritis in the United States: a population-health perspective: a population-based review of the fourth most common cause of hospitalization in U.S. adults. Orthop Nurs 2012; 31 (2) 85-91
    Google Scholar
  • 10 Losina E, Thornhill TS, Rome BN, Wright J, Katz JN. The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic. J Bone Joint Surg Am 2012; 94 (3) 201-207
    CrossrefPubMedGoogle Scholar
  • 11 Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med 2015; 162 (1) 46-54
    CrossrefPubMedGoogle Scholar
  • 12 Mazières B, Bard H, Ligier M, Bru I, d'Orsay GG, Le Pen C. Medicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: the MESSAGE study. Joint Bone Spine 2007; 74 (5) 453-460
    CrossrefPubMedGoogle Scholar
  • 13 Hatoum HT, Fierlinger AL, Lin SJ, Altman RD. Cost-effectiveness analysis of intra-articular injections of a high molecular weight bioengineered hyaluronic acid for the treatment of osteoarthritis knee pain. J Med Econ 2014; 17 (5) 326-337
    CrossrefPubMedGoogle Scholar
  • 14 Weinstein AM, Rome BN, Reichmann WM , et al. Estimating the burden of total knee replacement in the United States. J Bone Joint Surg Am 2013; 95 (5) 385-392
    CrossrefPubMedGoogle Scholar
  • 15 Waddell DD, Bricker DC. Total knee replacement delayed with Hylan G-F 20 use in patients with grade IV osteoarthritis. J Manag Care Pharm 2007; 13 (2) 113-121
    PubMedGoogle Scholar
  • 16 Waddell DD, Joseph B. Delayed total knee replacement with hylan G-F 20. J Knee Surg 2014;
    PubMedGoogle Scholar
  • 17 Altman RD, Lim S, Steen R, Dasa V. Intra-articular hyaluronic acid delays total knee replacement in patients with knee osteoarthritis: Evidence from a large U.S. health claims database. Osteoarthritis Cartilage 2015; 23 (Suppl. 02) 403-404
    PubMedGoogle Scholar
  • 18 Whitman CS, Allen D, Comadoll JL, Thomason HC, Oweida SJ. A retrospective study of SUPARTZ and repeat treatment of osteoarthritis pain in the knee. J Manag Care Med 2010; 13: 43-47
    PubMedGoogle Scholar
  • 19 Turajane T, Amphansap T, Labpiboonpong V, Maungsiri S. Total knee replacement following repeated cycles of intra-articular sodium hyaluronate (500–730 Kda) in failed conservative treatment of knee osteoarthritis: a 54-month follow-up. J Med Assoc Thai 2009; 92 (Suppl. 06) S63-S68
    PubMedGoogle Scholar
  • 20 Mar J, Romero Jurado M, Arrospide A, Enrique Fidalgo A, Soler López B. [Cost-analysis of viscosupplementation treatment with hyaluronic acid in candidate knee replacement patients with osteoarthritis]. Rev Esp Cir Ortop Traumatol 2013; 57 (1) 6-14
    PubMedGoogle Scholar
  • 21 Turajane T, Labpiboonpong V, Maungsiri S. Cost analysis of intra-articular sodium hyaluronate treatment in knee osteoarthritis patients who failed conservative treatment. J Med Assoc Thai 2007; 90 (9) 1839-1844
    PubMedGoogle Scholar
  • 22 Jones CA, Beaupre LA, Johnston DW, Suarez-Almazor ME. Total joint arthroplasties: current concepts of patient outcomes after surgery. Rheum Dis Clin North Am 2007; 33 (1) 71-86
    CrossrefPubMedGoogle Scholar
  • 23 Losina E, Walensky RP, Kessler CL , et al. Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med 2009; 169 (12) 1113-1121 , discussion 1121–1122
    CrossrefPubMedGoogle Scholar
  • 24 Wylde V, Dieppe P, Hewlett S, Learmonth ID. Total knee replacement: is it really an effective procedure for all?. Knee 2007; 14 (6) 417-423
    CrossrefPubMedGoogle Scholar